focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Jun 2009 14:52

RNS Number : 2171T
ReGen Therapeutics PLC
02 June 2009
 



2nd June 2009

REGEN THERAPEUTICS PLC 

("ReGen" or the "Company"; Ticker: (RGT))

TR-1(i): NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached (ii):

ReGen Therapeutics Plc

 

2. Reason for the notification:

An acquisition or disposal of voting rights 

 

3. Full name of person(s) subject to the notification obligation (iii):

Barclays PLC

 

4. Full name of shareholder(s) (if difference from 3):

Barclays Stockbrokers Ltd

 

5. Date of the transaction and date on which the threshold is crossed or reached (v):

29th May 2009

 

6. Date on which issued notified:

2nd June 2009

 

7. Threshold(s) that is/are crossed or reached:

12% to 13%

 

8. Notified details 

A: Voting rights attached to shares

Class/type of share if possible using the ISIN Code GB00B28XMY25

Situation Previous to the triggering transaction (vi) -

Number of Shares 3,175,133

Number of Voting Rights (viii) 3,175,133

Resulting situation after the triggering transaction (viii) -

Number of Shares 3,375,133

Number of Voting Rights - Direct (x) N/A

Number of Voting Rights - Indirect (xi) 3,375,133

% of voting rights - Direct N/A

% of voting rights - Indirect 13.22

B: Financial Instruments

Resulting situation after the triggering transaction (xii)

Type of financial instrument N/A

Expiration date (xiii) N/A

Exercise/Conversion Period/Date (xiv) N/A

Number of voting rights that may be acquired if the 

instrument is exercised/converted N/A

% of voting rights N/A

Total (A+B)

Number of voting rights 3,375,133

% of voting rights 13.22

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv): Barclays Stockbrokers Ltd

Proxy Voting:

 

10. Name of the proxy holder: N/A

 

11. Number of voting rights proxy holder will cease to hold: N/A

 

12. Date on which proxy holder will cease to hold voting rights: N/A

 

13. Additional information: N/A

 

14. Contact name: Geoff Smith

 

15. Contact telephone number: 0207 116 2913

For further information:

For further information, please contact: Percy Lomax ReGen Therapeutics Plc Tel: 020 7153 4920 Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel: 020 7628 3396 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEADKAELPNEFE
Date   Source Headline
2nd Mar 201812:09 pmRNSStatement re broker
22nd Jan 20187:00 amRNSPlacing
16th Jan 20187:00 amRNSPlacing
15th Dec 20177:00 amRNSPlacing and Issue of Equity
8th Dec 20177:00 amRNSMilciclib Phase 2a Trial Update
27th Nov 20177:00 amRNSPlacing
23rd Nov 20177:00 amRNSPhase II Clinical Trial Update
20th Nov 20177:00 amRNSSubscription
29th Sep 20177:00 amRNSInterim Results for Six Months Ended 30 June 2017
6th Sep 20177:00 amRNSA Proprietary Oral Formulation of Foralumab
31st Aug 201711:07 amRNSGrant of options - Director's dealing
16th Aug 20177:00 amRNSConversion of outstanding loan notes
28th Jul 20177:00 amRNSPublication of Research Article on Foralumab
19th Jul 20177:00 amRNSInitiation of a Phase IIa Clinical Trial
12th Jul 20177:00 amRNSProposed changes to CLNs and Warrant Terms
29th Jun 201711:21 amRNSResult of AGM
12th Jun 20177:00 amRNSAppointment of Dr Kunwar Shailubhai as CEO
8th Jun 201710:02 amRNSNOTIFICATION OF MAJOR INTEREST IN SHARES
8th Jun 20178:14 amRNSBcl-3 pre-clinical update and Director's dealing
1st Jun 20177:00 amRNS2016 Annual Report and Accounts and notice of AGM
23rd May 20177:00 amRNSFinancial Results for Year Ended 31 December 2016
24th Apr 20177:14 amRNSAnnounces Approval of a Phase II Clinical Trial
21st Apr 20177:00 amRNSAnnounces Publication of Milciclib Clinical Trial
24th Mar 20177:00 amRNSExercise of Warrants & Issue of Equity
14th Mar 20177:00 amRNSArun Sanyal appointed to Scientific Advisory Board
16th Jan 20177:00 amRNSWarrant Expiry - Reminder
3rd Jan 20177:00 amRNSTiziana Life Sciences in-licenses NI-1201
16th Nov 20167:00 amRNSNew Data with Foralumab
7th Nov 201612:29 pmRNSGrant of options
29th Sep 20167:00 amRNSHalf-year Report
15th Sep 20167:00 amRNSConfirmation of Capital Reduction
18th Aug 20167:00 amRNSChange of Registered Office
18th Jul 20167:00 amRNSTiziana acquires a unique bio-repository
30th Jun 201612:47 pmRNSResult of AGM
29th Jun 20167:00 amRNSIssue of Equity
10th Jun 201610:18 amRNSGrant of options and realisation bonus
7th Jun 20167:00 amRNSFinal Results
1st Jun 20167:00 amRNSPartnership with Cardiff Researchers Wins Award
19th May 20167:00 amRNSJournal review of anti - CD3 monoclonal antibodies
4th May 20167:00 amRNSAppointment of Dr. Robert Evans
28th Apr 20167:00 amRNSExercise of Warrants & Issue of Equity
4th Apr 20167:00 amRNSChief Financial Officer Appointed
15th Mar 20167:00 amRNSCo-Founder and NED Prof Chris McGuigan Passes Away
16th Feb 20164:40 pmRNSSecond Price Monitoring Extn
16th Feb 20164:35 pmRNSPrice Monitoring Extension
13th Jan 20167:00 amRNSFund raising
11th Jan 20167:00 amRNSDevelopment plans for foralumab & SAB appointments
8th Jan 20167:00 amRNSUpdate on Tiziana's Bcl-3 inhibitor
9th Dec 20158:00 amRNSAppoints James F. Tripp as Chief Operating Officer
8th Dec 20157:00 amRNSFund raising

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.